Medical treatment of levodopa-induced dyskinesia (LID) in Parkinson's disease (PD) is an unmet need. ADS-5102 (amantadine) extended-release capsules is being developed for the treatment of LID in patients with PD.Evaluate the long-term safety and tolerability of 274 mg ADS-5102 for LID in PD.In an ongoing, open-label safety study (NCT02202551), PD patients with LID received 274 mg of ADS-5102 once daily at bedtime. Patients were recruited from previous ADS-5102 trials. In addition, patients were enrolled who were ineligible for previous ADS-5102 trials due to previous implantation of deep-brain stimulation (DBS) devices. The primary outcome measure was safety assessed through adverse events (AEs). Efficacy was assessed using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Part IV and its subparts.For this interim analysis, 223 patients received ADS-5102 for a mean duration of 348 (SD 182) days. The most common AEs included falls (25.1

作者：Robert A, Hauser；Rajesh, Pahwa；Caroline M, Tanner；Wolfgang, Oertel；Stuart H, Isaacson；Reed, Johnson；Larissa, Felt；Mary Jean, Stempien

来源：Journal of Parkinson's disease 2017 年 7卷 3期